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CARDIAC TRANSPLANT 
CORONARY ARTERY 
DISEASE 
A multivariable analysis of 
pretransplantation risk 
factors for disease 
development and morbid 
events 
Coronary artery disease after cardiac transplantation is a major obstacle to 
long-term survival. The development and progression of coronary artery disease 
after cardiac transplantation was analyzed in 217 consecutive patients undergoing 
transplantation. The actuarial freedom from any coronary artery disease (by 
angiography or autopsy) was 81% at 2 years and 20% at 8 years after transplanta- 
tion. Coronary artery disease was more prevalent in male than female patients (30% 
versus 50% free of coronary artery disease at 5 years, p = 0.01). By multivariable 
analysis, pretransplantation risk factors identified for coronary artery disease 
included pretransplantation positive cytomegalovirus serologic status of the recip- 
ient (p = 0.002) and older donor age (p = 0.07). Progression of coronary artery 
disease was variable in both time of onset and rate. Earlier detection did not result 
in more rapid progression. Coronary events severe enough for retransplantation 
(n --- 8) and/or death from coronary artery disease (n = 9) occurred in 15 patients, 
of whom four underwent retransplantation. The actuarial freedom from coronary 
events was 88% at 5 years and 79% at 8 years. By multivariable analysis, only male 
recipient (p = 0.05) was a risk factor for coronary events. Seven of the 15 patients 
(47%) with coronary events died suddenly of coronary artery disease without prior 
angiographic evidence of severe coronary disease. Coronary artery disease is 
progressive. Improved surveillance methods are required to detect he disease and 
institute timely intervention to prevent he occurrence of unanticipated eath. 
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p osttransplantation coronary artery disease 
(CAD) is one of the major obstacles to long-term 
survival after cardiac transplantation. Available in- 
formation suggests that the process is initiated by 
immune-mediated injury to the endothelium of the 
coronary vessels, TM but the final expression of the 
injury as CAD is undoubtedly a complex interplay 
between atherogenic factors and the immunologic 
milieu created by donor and recipient interaction. 
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To better understand the incidence of, risk factors 
for, and progression of CAD after cardiac transplan- 
tation in the current era, we undertook the following 
study. The study aims included the determination of
the prevalence and pretransplantation risk factors 
for CAD after cardiac transplantation, analysis of 
the progression of CAD, and identification of risk 
factors for serious CAD events such as death and 
retransplantation. 
Patients and methods 
Patient population. Between November 1981 and Jan- 
uary 1, 1991, 217 patients underwent cardiac transplanta- 
tion at The University of Alabama at Birmingham. Sev- 
enteen patients (nine of whom died early) did not have 
information regarding the presence of CAD in their initial 
transplanted heart and were excluded from the analysis. 
Consequently, the analysis includes 200 patients. Fol- 
low-up for this study was complete through June 30, 1992. 
Immunosnppression therapy. From 1981 through 
1987, immunosuppression included azathioprine and 
prednisone. Between 1984 and 1987, cyclosporine arid 
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Fig. 1. Actuarial (Kaplan-Meier) freedom from the an- 
giographic (or autopsy) appearance of any cardiac trans- 
plant CAD (angiographic score greater than 0). Open 
circles represent actuarial appearance of CAD. The solid 
line represents he parametric estimate surrounded by the 
70% confidence limits (dashed lines). UAB, University of 
Alabama at Birmingham. 
prednisone were used, and from 1987 to 1991, triple-drug 
immunosuppression consisting of cyclosporine, azathio- 
prine, and prednisone was used. Induction therapy was 
used throughout the time frame with either rabbit anti- 
thymocyte globulin or OKT3. Acute cardiac rejection was 
managed initially with intravenous methylprednisolone 
sodium succinate (Solu-Medrol) for 3 days. Refractory or 
recurrent episodes of rejection were managed with ste- 
roids and cytolytic therapy (rabbit antithymocyte globulin 
or OKT3), and in the latter part of the experience 
methotrexate and total lymphoid irradiation were also 
used. 
Data collection. A number of pretransplantation demo- 
graphic, clinical, donor, and donor/recipient matching 
variables were collected (see Appendix A). 
The presence and extent of CAD was assessed by 
posttransplantation coronary arteriograms (n = 633), 
autopsy reports (n = 69), and explanted hearts (n = 
12). All available angiograms on all patients were 
examined by two of the investigators and each was 
scored according to the extent of CAD (see CAD 
scoring system). Throughout this experience, a general 
protocol of yearly coronary angiography was conducted 
for surveillance of CAD development. From approxi- 
mately 1987 through 1991, additional surveillance an- 
giograms were obtained at 6 weeks and 6 months after 
transplantation. 
Each patient was assessed for the development of 
morbid or fatal events related to CAD. These "CAD 
events" included eath resulting from CAD, retransplan- 
tation resulting from CAD, and consideration f retrans- 
plantation because of CAD (but not actually performed 
because of extenuating medical circumstances). 
CAD scoring system. A scoring system was developed 
to grade the angiographic severity of CAD in the epicar- 
dial arteries and also take into account he impact of 
specific disease on overall myocardial perfusion. The 
severity of angiographic disease was graded (0 to 5) in 17 
segments of the major coronary arteries and their epicar- 
dial branches. A weighting factor (maximum of 4) was 
assigned to each coronary artery segment on the basis of 
the relative importance of the lesion with respect o 
myocardium supplied. The segment score and the weight- 
ing factor were multiplied and then all were summed to 
generate a total angiographic s ore (see Appendix B). In 
general, ascore exceeding 15 indicated severe three-vessel 
CAD. The angiograms were also categorized according to 
the presence or absence important disease in each of the 
three major coronary artery systems. A score of 4 or more 
in the left anterior descending or circumflex territory and 
a score of 3 in the right coronary system were considered 
indicative of important disease in that territory (see 
Appendix B). 
Data analysis. The data were examined by means of 
standard contingency tables and Kaplan-Meier actuarial 
analysis. Multivariable analyses were then performed in 
the hazard function domain 5 to identify potential pre- 
transplantation risk factors associated with the angio- 
graphic appearance of any disease and CAD events. The 
rate of progression of disease was analyzed by linear and 
nonlinear regression. 
Results 
Incidence of cardiac transplant CAD. Sixty-eight 
patients had angiographic or autopsy evidence of 
cardiac transplant CAD (angiographic score greater 
than 0) over the 10-year study period. At 1 year and 
8 years after transplantation, 91% and 20%, respec- 
tively, of patients were free of angiographic CAD 
(Fig. 1). The hazard function indicates a progres- 
sively rising risk of developing CAD (Fig. 2). 
Risk factors for CAD. By univariate analysis, 
female patients had greater freedom from CAD 
than did male recipients (Fig. 3). However, by 
multivariable analysis, the only pretransplantation 
risk factors identified for the development of CAD 
were a positive pretransplantation cytomegalovirus 
(CMV) serologic status in the recipient and older 
donor age (Table I). A non-risk-adjusted compari- 
son of freedom from CAD stratified by pretrans- 
plantation CMV serologic status suggests that the 
effect of pretransplantation CMV serology is appar- 
ent after about 4 years (Fig. 4). The effect of donor 
age on the subsequent development of CAD was 
most pronounced for donors older than 35 years 
(Fig. 5). Among donors older than 35 years, 16 were 
35 to 40 years and 4 were 40 to 45 years. No 
relationship was identified between recipient age 
and development of CAD. 
Severity and progression of CAD. Considering all 
sources of CAD information (angiogram, autopsy, 
explanted heart), more than 70% of studies showed 
no CAD, 15% showed a score of i to 5, and less than 
6% had a score exceeding 10 (Table II). Among the 
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Fig. 2. Hazard function for the angiographic appearance 
of any cardiac transplant CAD, represented onthe vertical 
axis as the number of patients per month in whom any CAD 
develops. It consists of a constant and a late phase. The 
hazard function (instantaneous ri k) is represented by the 
solid line and is surrounded by the 70% confidence limits 
(dashed lines). UAB, University of Alabama t Birmingham. 
Tab le  I. Risk factors for cardiac transplant CAD 
p Value 
R&k factors Constant Late 
Recipient pretransplantation positive - -  0.0007 
CMV status 
Donor  age (older) - -  0.03 
studies revealing CAD, 37% of these had important 
single-vessel disease, 5% two-vessel disease, and 
13% three-vessel disease. In 45%, the CAD was 
considered trivial (Table III). Of the 69 autopsied 
hearts, 51 (74%) had no evidence of CAD (score 0), 
4 had mild CAD (score 1 to 10), 3 had a score of 10 
to 15, and 11 (16%) had severe CAD (score ->15). 
Analyzed according to number of vessels involved, 
4% of the autopsied hearts had single-vessel disease, 
3% two-vessel disease, and 17% three-vessel dis- 
ease. For the overall group, the mean CAD score 
increased over time, but even at 8 years the mean 
CAD score remained less than 10. Throughout the 
study period, the mean CAD score for male patients 
was consistently greater than that for female pa- 
tients (Fig. 6). To examine the rate of progression of 
CAD relative to the first appearance of disease, we 
examined the rate of increase in angiographic CAD 
score for each patient with CAD as a function of the 
year after transplantation i  which CAD first ap- 
peared (Fig. 7). Although there is considerable 
variability, it is noteworthy that earlier appearance 
of CAD (for example, within the first 2 years) was 
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Fig. 3. Actuarial (Kaplan-Meier) freedom from the an- 
giographic (or autopsy) appearance of any cardiac trans.- 
plant CAD stratified by recipient gender. Circles, Female; 
squares, male. The error bars indicate 70% confidence 
limits. UAB, University of Alabama t Birmingham. 
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Fig. 4. Actuarial (Kaplan-Meier) freedom from the 
angiographic (or autopsy) appearance of any cardiac 
transplant CAD (angiographic s ore greater than 0) strati- 
fied by recipient pretransplantation CMV serologic status. 
Circles, negative; squares, positive. Error bars indicate 70% 
confidence limits. UAB, University of Alabama t Birming- 
ham. 
not associated with more rapid disease progression. 
Particularly after the second year, the rate of pro- 
gression among groups was similar. 
Invasive therapy  for CAD. Seven patients under- 
went percutaneous transluminal ngioplasty (PTCA) 
as palliative therapy for posttransplantation vascu- 
lopathy. Initial PTCA occurred 2.5 to 7.0 years 
(median 4.1 years) after cardiac transplantation. 
Three patients (38%) required multiple PTCAs 
(two, two, and three). Two patients underwent 
coronary bypass grafting after PTCA; one patient in 
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Fig. 5. Actuarial (Kaplan-Meier) freedom from angio- 
graphic (or autopsy) appearance ofany cardiac transplant 
CAD stratified by donor age. Circles, less than 20 years; 
squares, 20 to 35 years; triangles, greater than 35 years. The 
error bars indicate 70% confidence limits. UAB, University 
of Alabama at Birmingham. 
Table II. CAD scores 
CAD index* n % of 714 
0 521 73 
1-5 107 15 
6-10 46 6 
11-20 23 3 
21-30 10 1.4 
31-40 6 0.8 
41-50 1 0.1 
Total 7147 100 
*Maximum possibIe score = 105. 
?Includes coronary arteriograms (n = 633), autopsy reports (n = 69), and 
explanted hearts (n = 12). 
Table III. Number of arteries affected by CAD 
Number of major coronary 
artery systems with disease* 
CAD index 0 1 2 3 Total 
0 521 0 0 0 521 
1-5 83 24 0 0 107 
6-10 3 42 1 0 46 
11-15 0 6 7 2 15 
16-20 0 0 1 7 8 
>20 0 0 1 16 17 
Total 607 72 10 25 714 
*See Patients and methods (CAD scoring system). 
shock on an emergency basis on the same day after 
attempted PTCA and the other 1 year after PTCA. 
Both patients died. 
CAD events after cardiac transplantation. Among 
the 200 patients, 15 CAD events occurred (see again 
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Fig. 6. Relationship between mean CAD score and in- 
creasing time from transplantation stratified by recipient 
gender. Circles, Male; squares, female. The error bars 
indicate 70% confidence limits. UAB, University of Ala- 
bama at Birmingham. 
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score according to the year of first angiographic detection 
of CAD. UAB, University of Alabama at Birmingham. 
Patients and methods). Four patients underwent 
retransplantation for CAD, four additional patients 
were considered for retransplantation because of 
extensive CAD but were denied the operation be- 
cause of coexisting medical problems (two of these 
subsequently died of CAD), and seven patients died 
unexpectedly of CAD (identified at autopsy) who 
did not have extensive CAD identified by previous 
angiography. Thus 47% of serious CAD events were 
unanticipated on the basis of routine surveillance 
angiography. 
Of the total of 95 deaths from all causes in the 217 
transplant recipients, only nine could be attributed 
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to CAD. Of the 19 deaths occurring between the 
third and eighth years after transplantation, only 
four (21%) were due to CAD. The remaining causes 
of death more than 3 years after transplantation 
were malignancy (n = 3), rejection (n = 4), pulmo- 
nary embolism (n = 1), suicide (n = 1), cirrhosis 
(n = 1), renal failure (n = 1), cerebral hemorrhage 
(n = 1), multisystem failure (n = 1), multifocal 
leukoencephalopathy (n --- 1), and unknown (n = 1). 
The actuarial and parametric freedom from a 
serious CAD event was 71% at 8 years (Fig. 8). The 
linear slope of the hazard function indicates a 
gradually increasing risk of such an event over time 
(Fig. 9). By multivariable analysis, the only pretrans- 
plantation risk factor identified for a subsequent 
CAD event was recipient male gender (p = 0.05). 
At 6 years, nearly 30% of male recipients had a 
CAD event compared with about 2% among female 
recipients (Fig. 10). 
Discussion 
Limitations of the study. In this study, coronary 
arteriography formed the basis of detection of post- 
transplantation CAD. Although recognized as the 
standard iagnostic technique for coronary arteri- 
opathy, angiography is known to be a less sensitive 
method of coronary disease detection than autopsy 
studies 6-8 and the more recent technique of intra- 
coronary ultrasonic imaging. 9'10 The relative insen- 
sitivity of coronary arteriography may relate in part 
to the pathologic basis of posttransplantation vascu- 
lopathy, in that the primary lesion is a proliferative 
response of the vascular wall smooth muscle cells, 
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which is distributed throughout the length of the 
coronary arteries. 11' 12 Angiographically, this prolif.- 
eration may appear as concentric luminal narrowing 
in small intramyocardial coronary arteries with 
abrupt ending of distal branches. 13' 14 The diffuse 
nature of the process with resultant narrowing of 
luminal caliber throughout the length of coronary 
vessels contributes to the difficulty of angiographic 
detection of abnormalities. In addition to this pro- 
liferative response, there is a superimposed athero- 
sclerotic component hat results in the eccentric 
lesions more typical of native CAD. 6 Thus the 
findings in this study relative to the incidence of 
CAD are likely a minimum estimate. 
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Regarding the risk factor analysis, this study ex- 
amined only pretransplantation variables as predic- 
tors of posttransplantation CAD. The aim of this 
analysis was to identify patient subsets before trans- 
plantation who may be more vulnerable to post- 
transplantation CAD and events. Further studies of 
this type will be necessary to incorporate detailed 
multivariable analyses of posttransplantation phe- 
nomena, including such variables as rejection 
history, CMV disease, complex lipid alterations, 
tobacco habits, and development of obesity. Previ- 
ous studies have alluded to some of these factors 
in the development of posttransplantation vascu- 
lopathy.n' 15-19 
This study is also limited by a relatively small 
number of patients at a single institution. There 
would be obvious advantages to a multiinstitu- 
tional study of posttransplantation vasculopathy, 
which might more accurately reflect he variability 
of this disease. On the other hand, however, this 
study has the advantage of complete review of all 
angiograms in the experience. Other reports in 
the literature have often relied totally on anglo- 
graphic reports from the patient records rather 
than a separate individual review of all angio- 
grams. 
Incidence and pretransplantation risk factors for 
cardiac transplant CAD. The incidence of anglo- 
graphically apparent CAD in this study of 80% at 8 
years is consistent with the findings of other re- 
ports.17, 20, 21 However, the true incidence of at least 
the proliferative component is much greater. In a 
study of autopsy and explanted heart material, es- 
sentially all patients had important coronary artery 
lesions by 12 months after transplantation. 22 
The finding of older donor age as a risk factor for 
CAD development was previously noted by Gao and 
colleagues 23in a univariate analysis, but the effect 
was weak. In the present study, the effect of older 
donor age was most prominent for donors older 
than 35 years, although the number of older donors 
in this experience was limited. Presumably, this 
donor age effect relates to an increased propensity 
for atherosclerotic changes in the older donor. 
The association between recipient pretransplan- 
tation CMV-positive serology and the development 
of CAD is provocative. It is particularly interesting 
that the apparent effect of CMV serology was 
manifest only after about 4 years (see again Fig. 4). 
Perhaps this delay relates in some way to the long 
dormant interval typically observed before the acti- 
vation of CMV disease. Although this study did not 
address the possible impact of posttransplantation 
CMV disease or seroconversion, Loebe and col- 
leagues 15 noted a higher incidence of positive CMV 
serology among patients with coronary vasculopa- 
thy. A number of clinical studies have reported an 
association between CMV infection and the subse- 
quent development of CAD. 15'24-26 It has been 
postulated that CMV may promote graft intimal 
disruption by modulating major histocompatibility 
antigens, endothelial monocyte antigens, endothe- 
lial cell antigenicity, or adhesion molecules, thus 
producing an enhanced immunologic target. 11'27 
CMV nucleic acids have been detected in the endo- 
thelial cells and smooth muscle cells of the coronary 
arteries in a significant proportion of hearts with 
transplant vasculopathy. 2s 
CAD progression. Little published ata is avail- 
able regarding the details of CAD progression after 
cardiac transplantation. I  this study, both the time 
of angiographic appearance and the rate of progres- 
sion after disease-free intervals were variable. It is of 
interest, however, that earlier detected CAD was 
not associated with a more accelerated rate of CAD 
progression (see again Fig. 7). These findings are 
consistent with a hypothesis that incorporates im- 
munologic events (manifesting at a variable period 
after transplantation) i itiating intimal damage with 
superimposed development of accelerated athero- 
sclerosis as an independent phenomenon. Support 
or rejection of this hypothesis will require further 
complex analyses. 
Morbid and fatal CAD events. The important 
mortality associated with the development of post- 
transplantation CAD has been reported by 
Uretsky, 29 Keogh, 3° and others. Keogh and col- 
leagues 3° reported an actuarial survival of 44% at 2 
years after angiographic appearance of greater than 
40% stenosis in one or more major epicardial ves- 
sels. Survival was particularly poor in patients with 
extensive three-vessel disease. The CAD event-free 
survival in the present study was 71% at 8 years. This 
rate is surprisingly high given the mere 20% free- 
dom from angiographically detectable CAD by 8 
years and may partially reflect an aggressive use of 
PTCA for posttransplantation CAD. In a multiinsti- 
tutional study, Halle and colleagues 31reported fa- 
vorable intermediate-term esults of PTCA therapy 
in this setting. Despite the serious implications of 
CAD development, coronary vasculopathy ac- 
counted for a small proportion of late mortality 
(20% of deaths occurring 3 to 8 years after trans- 
plantation). This mortality is somewhat lower than 
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might be expected given the disease incidence and 
its progressive nature, and it underscores the impor- 
tance of also focusing diagnostic and therapeutic 
efforts at other causes of late mortality, such as 
rejection, infection, and malignancy. 
The inadequacy of yearly surveillance coronary ar- 
teriography as a method for preventing CAD mortality 
is supported by the important incidence of CAD- 
related deaths that were unanticipated by previous 
angiographic studies. Thus there dearly is a need for 
more sensitive invasive and noninvasive t chniques for 
detection of the posttransplantation CAD process. 
From this study we draw the following inferences: 
• CAD by angiography is detected by 8 years in more 
than 80% of long-term survivors of cardiac trans- 
plantation, and it is more prevalent among recipients 
with positive CMV serology and older donor hearts. 
• The rate of progression of CAD is variable, and 
earlier detection does not predict more rapid 
progression of disease. 
• Despite the frequency of CAD, serious coronary 
events (relisting for retransplantation r CAD-re- 
lated death) occur in only about 25% of patients by 
8 years and are more likely among male recipients. 
• Cardiac transplant CAD accounts for approxi- 
mately 20% of deaths occurring 3 to 8 years after 
transplantation. 
• Despite a protocol of routine yearly surveillance 
angiograms, more than 40% of coronary events 
present as sudden or unexpected eath without 
previously detected CAD. 
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Discuss ion 
Dr. Severi P. Mattila (Helsinki, Finland). Vasculopathy 
is one of the most important factors influencing the late 
outcome of patients after cardiac transplantation. Our 
experience is limited to 150 patients, with 78% survival at 
8 years. In one patient with CMV who died we found 
extreme vasculopathy with enormous intimal thickening 
of the coronary arteries. Therefore, we decided to review 
all of the cases of symptomatic CMV infection, as well as 
doing endomyocardial biopsy and coronary angiography, 
and we compared these two groups of patients. 
Table I summarizes the occurrence of the occlusive 
changes in coronary arteries of the patients with CMV 
infection and in the other group of patients. At 2 years 
there was a statistically significant difference between the 
two groups. Thus in our experience CMV infection seems 
to accelerate the vasculopathy in the coronary arteries. 
Table I1 shows the histologic part of our study, and it 
confirms the coronary arteriographic study. The intimal 
thickening developed earlier in those patients with CMV 
infection, but at 4 years there was no statistically signifi- 
cant difference in our series. 
We can conclude that CMV infection accelerates the 
appearance of coronary vasculopathy after heart transplan- 
tation, and it can be seen in both coronary arteriograms and 
endomyocardial biopsy specimens of the small arteries. 
Dr. McGiflin. The association between CAD after cardiac 
transplantation a d CMV infection has been demonstrated 
before, and you have provided more confirmatory informa- 
tion. Obviously some complex interplays are involved, with 
immunologic risk factors and also probably the more tradi- 
tional atherosclerotic r sk factors. It is interesting to specu- 
late on why CMV should be associated with CAD. Perhaps 
it is in part the result of endothelial damage of the coronary 
arteries producing an inflammatory esponse with the pro- 
duction of cytokines, resulting in the proliferative process 
that we see in the coronary arteries. 
Table I. The number of angiograms analyzed and 
the frequency of cardiac allografi vasculopathy 
(CAV) detected uring the 4 posttransplant years 
Year after cardiac 
transplantation 
1 2 3 4 
Angiograms 50 31 25 9 
CMV patients 28 19 16 5 
CAV total (%) 16 39 52 56 
CAV, CMV (%) 25* 53* 56t 60]" 
CAV, CMV-free (%) 5* 17" 44t 50t 
*p < 0.05. 
tNot significant. 
Table II. The number of endomyocardial biopsy 
(EMB) specimens analyzed and the frequency of 
vascular changes (VC) observed uring the 4 
posttransplantation years 
Year after cardiac transplantation 
1 2 3 4 
EMB specimens 43 28 25 8 
CMV patients 26 19 16 4 
VC total (%) 74 79 88 100 
VC, CMV (%) 77* 84* 81 100 
VC, CMV-free (%) 71" 67* 100 100 
*p < 0.05. 
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Dr. Norman E. Shumway (Stanford, Calif.). In any 
instance did you detect angina in the patients? We have 
wondered about that for many years. 
Dr. McGitfin. Yes, some of these patients did have 
classic angina, and others had angina-equivalent symp- 
toms. I guess this response may suggest some reinnerva- 
tion of the heart. That I the only evidence of reinnervation 
that we have observed. 
Dr. Shumway. We thought hat these symptoms might 
be due more to left atrial distention in patients who are 
having moderate cardiac failure with their CAD rather 
than an indication of true reinnervation. 
Dr. Robert M. Mentzer, Jr. (Madison, Wis.). One of the 
problems with this disease is that it can be difficult to 
differentiate typical atherosclerosis from cardiac allograft 
vasculopathy. This problem is going to become more 
complex as we use organs from older donors. Currently, 
we use angiography to differentiate the two diseases. 
This technique, however, may not be the best way of 
assessing progression of disease despite the fact that 
transplant vasculopathy differs pathologically from typ- 
ical atherosclerosis. One diagnostic alternative that may 
give us more insight into differentiation and progression 
is intravascular ultrasography. We and others are be- 
ginning to realize that this may be a much better 
technique for diagnosing transplant vasculopathy as 
well as monitoring progression. 
What has been your experience in the use of intravas- 
cular ultrasonography? Can you shed any light on new 
techniques for differentiating and following the course of 
the two diseases? 
Dr. McGittln. You are absolutely correct. Intracoronary 
ultrasonography is almost certainly more sensitive than 
angiography, which is very insensitive. We have not yet 
used intracoronary ultrasonography, but we will be start- 
ing that very soon. It will be interesting to see in a few 
years' time with the increased sensitivity of this test whether 
the same risk factors that we have demonstrated will also be 
operative when we are using a more sensitive method. 
Dr. Davis C. Drinkwater (Los Angeles, Calif.). We have 
noted another isk factor for transplant CAD. We recently 
reported at the International Society for Heart and Lung 
Transplantation Meeting that the preservation solution 
may be related as a cofactor with this process. We have 
better esults with our University of Wisconsin solution in 
terms of length of preservation a d functional outcomes, but 
we also saw a significant increase in the prevalence of 
coronary arterial vasculopathy at a 36-month mean fol- 
low-up in our first 100 patients in whom this solution was 
used. 
Do you have any information on the preservation solution, 
and did you vary it in your own patient population? 
Dr. McGitfin. I am familiar with the information that 
you presented in Italy, and it is very interesting. We did 
not include preservation solution as a risk factor in this 
multivariable analysis. 
Appendix A 
Variables for analysis 
Demographic: Age, gender, number of pregnancies, 
race, weight, height, body surface area. 
Clinical." Diagnosis, blood type, CMV serology, panel 
reactive antibody, immunosuppression protocol, choles- 
terol, triglyceride, tobacco use. 
Donor: Age, gender, race, weight, height, body surface 
area, blood type, pressors. 
Donor~recipient matching: Age, gender, race, body sur- 
face area, weight, blood type, crossmatch, uman leuko- 
cyte antigen mismatches. 
Multivariate quation for CAD 
Constant phase: intercept - 0.00859 
Late phase: donor age (years) 0.0897 _+ 0.0412, recipient 
pretransplantation p sitive CMV serology 2.22 _+ 0.65, ~- = 
1, a = 1, ~ = 1, 3' = 4.48, intercept = 1.013 × 10 - l °  
Multivariate quation for CAD event 
Late phase: male recipient 2.06 _+ 1.04, ~- = 1, 3' = 1, a = 
1, ~ = 2.01, intercept = 6.98 × 10 6. 
Appendix B. CAD score 
Each of the 17 portions of the coronary arteries is 
graded as follows: 
0 Normal 
1 Minor wall irregularities 
2 Stenosis <50% 
3 Stenosis >50% and <70% 
4 Stenosis >70% 
5 Occluded 
Diffuse narrowing is given a score of 2 unless there is a 
discrete stenosis that warrants a higher score. Numbers 
in parentheses in the table are for left dominant 
systems. 
Appendix B table 
Maximum 
Multiplication possible 
Vessel factor score 
Left main 4 20 
LAD 
Proximal 2 10 
Mid 1 5 
Distal 1 5 
First diagonal 2/3 
Second diagonal 2/3 
Third diagonal 2/3 
Left circumflex 
Proximal 2 (3) 10 (15) 
Mid 1 5 
First marginal 2/3 
Second marginal 2/3 10 
Third marginal 2/3 
RCA 
Proximal 2 (1) 10 (5) 
Mid 1 5 
Distal 1 5 
PDA 1 5 
LV branch 1 5 
Total 105 
LAD, Left anterior descending; RCA, right coronary artery; PDA, posterior 
descending artery; LV, left ventricular. 
